Literature DB >> 19230598

The effect of hydroxy metabolites of clarithromycin to the pharmacokinetic parameters, and determination of hydroxy metabolites ratio of clarithromycin.

Durisehvar Unal1, Aysen Fenercioglu, Latif Ozbay, Banu Ozkirim, Dilek Erol.   

Abstract

Clarithromycin is a broad-spectrum macrolide antibacterial agent which is effective both in vitro and in vivo against the major pathogens responsible for respiratory tract infections. Clarithromycin's principal metabolite is 14-(R) hydroxyclarithromycin (14-OH-clarithromycin). The other metabolite, namely 14-(S) hydroxyclarithromycin is inactive. The purpose of this study was to show the hydroxylation of CLA at the 14 position to form the R and S epimers and to determine the metabolic ratio of 14ROHCLA/CLA and 14SOHCLA/CLA for understanding the metabolization. This study suggest that in healthy adults, the individual variations in therapeutic responses to clarithromycin can be assumed by taking the drug and its metabolites ratios. Clarithromycin and metabolites ratios increase during metabolization.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19230598     DOI: 10.1007/BF03190879

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  6 in total

1.  Determination of clarithromycin in human plasma by liquid chromatography-electrospray ionization tandem mass spectrometry.

Authors:  Yao Jiang; Jiang Wang; Hao Li; Yingwu Wang; Jingkai Gu
Journal:  J Pharm Biomed Anal       Date:  2006-12-15       Impact factor: 3.935

2.  Bioequivalence revisited: influence of age and sex on CYP enzymes.

Authors:  Zourab Bebia; Shama C Buch; John W Wilson; Reginald F Frye; Marjorie Romkes; Alfred Cecchetti; Diego Chaves-Gnecco; Robert A Branch
Journal:  Clin Pharmacol Ther       Date:  2004-12       Impact factor: 6.875

3.  Oxidative metabolism of clarithromycin in the presence of human liver microsomes. Major role for the cytochrome P4503A (CYP3A) subfamily.

Authors:  A D Rodrigues; E M Roberts; D J Mulford; Y Yao; D Ouellet
Journal:  Drug Metab Dispos       Date:  1997-05       Impact factor: 3.922

4.  The levels of clarithromycin and its 14-hydroxy metabolite in the lung.

Authors:  D Honeybourne; F Kees; J M Andrews; D Baldwin; R Wise
Journal:  Eur Respir J       Date:  1994-07       Impact factor: 16.671

5.  Pharmacokinetics of clarithromycin in bronchial epithelial lining fluid.

Authors:  Eiki Kikuchi; Koichi Yamazaki; Junko Kikuchi; Naoki Hasegawa; Satoru Hashimoto; Akitoshi Ishizaka; Masaharu Nishimura
Journal:  Respirology       Date:  2008-03       Impact factor: 6.424

6.  Metabolism and disposition of clarithromycin in man.

Authors:  J L Ferrero; B A Bopp; K C Marsh; S C Quigley; M J Johnson; D J Anderson; J E Lamm; K G Tolman; S W Sanders; J H Cavanaugh
Journal:  Drug Metab Dispos       Date:  1990 Jul-Aug       Impact factor: 3.922

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.